Rexford Industrial Realty Inc
Change company Symbol lookup
Select an option...
REXR-A Rexford Industrial Realty Inc
DPW DPW Holdings Inc
IWN iShares Russell 2000 Value ETF
XNXCX Nuveen California Select Tax-Free Income Portfolio
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Small Cap Growth
Company profile

Rexford Industrial Realty, Inc. is a self-administered and self-managed real estate investment trust (REIT). The Company is focused on owning and operating industrial properties in Southern California infill markets. Through its controlling interest in its Rexford Industrial Realty, L.P. (Operating Partnership) and its subsidiaries, it owns, manages, leases, acquires and develops industrial real estate principally located in Southern California infill markets, and, from time to time, acquire or provide mortgage debt secured by industrial property. It owns a portfolio of approximately 236 properties with approximately 29.9 million rentable square feet. In addition, it manages approximately 20 properties with approximately one million rentable square feet.

This security is a preferred stock
Closing Price
$25.22
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
19,621
0

BIIB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Investors of Class Action and Encourages Investors to Contact the Firm

8:00 am ET November 23, 2020 (BusinessWire) Print

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Biogen securities pursuant between October 22, 2019 and November 6, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/biib.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab's effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the FDA's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/biib or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Biogen you have until January 12, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005580/en/

SOURCE: Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.